GERN
NASDAQ HealthcareGeron Corporation - Common Stock
Biotechnology
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
�� 市场数据
| 价格 | $1.68 |
|---|---|
| 成交量 | 21,774,648 |
| 市值 | 1.08B |
| 贝塔系数 | 0.670 |
| RSI（14日） | 69.4 |
| 200日均线 | $1.39 |
| 50日均线 | $1.63 |
| 52周最高 | $2.01 |
| 52周最低 | $1.04 |
| Forward P/E | 21.00 |
| Price / Book | 4.76 |
🎯 投资策略评分
GERN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 💰 Dividend Daddy (42/100) — 此策略 高股息率 + 低波动性.
评分最低的策略： 🐋 Institutional Whale (27/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 GERN in your text
粘贴任何文章、记录或帖子 — 工具将提取 GERN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.